"Quinolones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.
| Descriptor ID |
D015363
|
| MeSH Number(s) |
D03.633.100.810.835
|
| Concept/Terms |
Quinolones- Quinolones
- Quinolinones
- Ketoquinolines
- Oxoquinolines
|
Below are MeSH descriptors whose meaning is more general than "Quinolones".
Below are MeSH descriptors whose meaning is more specific than "Quinolones".
This graph shows the total number of publications written about "Quinolones" by people in this website by year, and whether "Quinolones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 5 | 0 | 5 |
| 2011 | 4 | 0 | 4 |
| 2012 | 1 | 3 | 4 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2017 | 5 | 2 | 7 |
| 2018 | 2 | 0 | 2 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 2 | 2 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Gastrointestinal Burden in Patients With Pancreatic Insufficient Cystic Fibrosis Before and After Elexacaftor/Tezacaftor/Ivacaftor Use. Pancreas. 2025 Nov-Dec 01; 54(10):e858-e862.
-
Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Can J Ophthalmol. 2022 02; 57(1):e6-e10.
-
Local Anti-PD-1 Delivery Prevents Progression of Premalignant Lesions in a 4NQO-Oral Carcinogenesis Mouse Model. Cancer Prev Res (Phila). 2021 08; 14(8):767-778.
-
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. J Cyst Fibros. 2021 03; 20(2):234-242.
-
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros. 2021 03; 20(2):333-338.
-
A Dilute and Shoot LC-MS/MS Method for Antipsychotics in Urine. J Anal Toxicol. 2020 May 18; 44(4):331-338.
-
Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. J Drugs Dermatol. 2018 Oct 01; 17(10):1051-1057.
-
Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018 07 01; 154(7):806-813.
-
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. J Cyst Fibros. 2018 03; 17(2):228-235.